A device developed at the Joseph Fourier University could be used to power drug delivery technologies and medical implants using energy created in vivo within the next decade, say researchers.
Rusnano and Nearmedic Plus will build a ‘nanomedicine’ production facility in Russia in a collaboration that fits with Government efforts to boost local drug manufacturing.
Tissue-based delivery tech developer Medgenics is in talks with Baxter Healthcare about new deal, but says continued focus on Factor VIII is not ‘mission critical’ to biopump platform.
Ugandan drugs maker Quality Chemical Industries Ltd (QCIL) is ready to manufacture HIV treatment Tenofovir in a bid to dominate the local antiretroviral market.
Medecins Sans Frontieres (MSF) wants Brazil to streamline its validation process for the API benznidazole after global stocks of the Chagas disease treatment drop to critical levels.
Solvias and RohnerChem have set up a research and manufacturing services partnership designed to accelerate the production, scale-up and commercialisation of APIs.
Peptide-based therapeutics specialists Unigene will focus on high valuation drug development and drug delivery opportunities after cutting loose its Site Directed Bone Growth (SDBG) patent portfolio.
Cambridge Major Laboratories Europe (CMLE) is set to start commercial API manufacturing at its facility in the Netherlands after approval by Dutch regulators.
The FDA is targeting companies that reformulate drugs to evade enforcement as it tries to crackdown on the 1000s of products marketed without approval.
Alkermes has celebrated the launch of its new Irish drug delivery and formulation business by winning a new multimillion dollar manufacturing contract with a ‘top 10 pharma.’
Use of deoxycholate to chemically disrupt influenza viruses during vaccine manufacture could be linked to adverse reactions in children, a journal reports.
Albemarle says it will increase what it charges for generic APIs from next month, citing increasing regulatory and testing costs as the main reasons for the hike.
Contract manufacturing organisation (CMO) Aurobindo Pharma has teamed up with Russian supplement maker OJSC Diod to establish a manufacturing joint-venture.
Marina Biotech has strengthened its nucleic acid-peptide drug delivery platform after being granted the allowance for patents application of a library of novel peptides.
AmerisourceBergen has bought informatics firm IntrinsiQ for $35m (€25m) continuing the spending spree it began earlier this week with the acquisition of market access consultancy Premier Source.
Japanese CMO Toyobo says it will increase capacity for injectable drugs to secure its position as a service provider in the expanding biopharmaceutical sector.
DMV-Fonterra excipients (DFE) will buy Indian manufacturer Brahmar Cellulose Private Limited (BCPL) to strengthen its position in the pharmaceutical excipient market and reduce costs.
German chemical maker Wacker Chemie is ramping up its sales operations in India, with the country’s rapidly expanding pharmaceutical sector being one of its key targets.
Chemicals maker Granules India says it will expand manufacturing capacity for oral solid dose (OSD) APIs and drug intermediates in a bid to better meet the needs of clients.
in-PharmaTechnologist presents a roundup of the latest drug delivery research, including bone marrow targeting nanoparticles and an imaging-treatment combo.
Catalent is to buy clinical trial supply assets from Aptuit for $410m (€285m) as it adds scale to handle the shift to preferred provider relationships.
Contract speciality chemical maker Chemspec International says it will ‘go private’ after being taken over by Halogen Limited, a holding company co-owned by members of its management board.